Loading…
Prognostic significance of HE4 expression in pulmonary adenocarcinoma
We investigated the possibility of human epididymis 4(HE4) to predict survival for patients with pulmonary adenocarcinoma. One hundred and thirty-seven patients with pulmonary adenocarcinoma underwent surgery in our institute from 2000 to 2008. We used immunohistochemical analysis to determine the e...
Saved in:
| Published in: | Tumor biology 2011-04, Vol.32 (2), p.265-271 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c436t-690ccd6df8ddd17c97573828a911238b0f323b7a63ce1d4201372baa9a50023d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c436t-690ccd6df8ddd17c97573828a911238b0f323b7a63ce1d4201372baa9a50023d3 |
| container_end_page | 271 |
| container_issue | 2 |
| container_start_page | 265 |
| container_title | Tumor biology |
| container_volume | 32 |
| creator | Yamashita, Shin-ichi Tokuishi, Keita Hashimoto, Takafumi Moroga, Toshihiko Kamei, Mirei Ono, Kiyoshi Miyawaki, Michiyo Takeno, Shinsuke Chujo, Masao Yamamoto, Satoshi Kawahara, Katsunobu |
| description | We investigated the possibility of human epididymis 4(HE4) to predict survival for patients with pulmonary adenocarcinoma. One hundred and thirty-seven patients with pulmonary adenocarcinoma underwent surgery in our institute from 2000 to 2008. We used immunohistochemical analysis to determine the expression of HE4 and compared with the clinicopathological factors and survival. Serum levels of HE4 in lung adenocarcinoma were investigated by enzyme immunometric assay. Fifty-seven of 137 cases (41.6%) were HE4 positive. It was found that there was no correlation between HE4 expression by immunohistochemistry and clinicopathological factors, however, adenocarcinoma subtype was significantly associated with HE4 expression. Sera in lung adenocarcinoma were significantly higher than in healthy control. Five-year disease-free survival in the HE4-positive group (44.6%) was significantly different from that in the negative group (82.3%,
p
= 0.001) by immunohistochemistry. The five-year overall survival rate was 60.1% in the HE4-positive group, as compared with 90.8% in the HE4-negative group (
p
= 0.001). In multivariate Cox regression analysis, positive HE4 protein expression was a worse prognosis factor of disease-free and overall survival (HR = 3.7, 95%CI = [1.7–8.4],
p
= 0.001; HR = 5.5, 95%CI = [1.8–17.2],
p
= 0.003, respectively), in addition to nodal status as a powerful value. When HE4 expression in adenocarcinoma cases except the BAC were analyzed, nodal status and HE4 expression were independent prognostic factors in disease-free and overall survivals. These data showed that HE4 expression is associated with a worse prognosis and is a possible prognostic factor of lung adenocarcinoma. |
| doi_str_mv | 10.1007/s13277-010-0118-5 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_853226255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2270899291</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-690ccd6df8ddd17c97573828a911238b0f323b7a63ce1d4201372baa9a50023d3</originalsourceid><addsrcrecordid>eNp1kE9LwzAYh4Mobk4_gBcpXjxV86dpmqOM6YSBHvQc0iQdGW1SkxX025vSqSB4CAm8T37v-z4AXCJ4iyBkdxERzFgOEUwHVTk9AnNUYJJDUsHj9B4rBa7IDJzFuIMQUc7LUzDDkFPCKJqD1UvwW-fj3qos2q2zjVXSKZP5Jluvisx89MHEaL3LrMv6oe28k-Ezk9o4r2RQ1vlOnoOTRrbRXBzuBXh7WL0u1_nm-fFpeb_JVUHKfV5yqJQudVNprRFTnFFGKlxJjhAmVQ0bgknNZEmUQbrAEBGGaym5pBBioskC3Ey5ffDvg4l70dmoTNtKZ_wQRUUJxiWmNJHXf8idH4JLwyUIM0w4RwlCE6SCjzGYRvTBdmk9gaAYDYvJsEgexWhYjMFXh-Ch7oz--fGtNAF4AmIqua0Jv53_T_0CmEGE1A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>852723991</pqid></control><display><type>article</type><title>Prognostic significance of HE4 expression in pulmonary adenocarcinoma</title><source>Publicly Available Content Database</source><creator>Yamashita, Shin-ichi ; Tokuishi, Keita ; Hashimoto, Takafumi ; Moroga, Toshihiko ; Kamei, Mirei ; Ono, Kiyoshi ; Miyawaki, Michiyo ; Takeno, Shinsuke ; Chujo, Masao ; Yamamoto, Satoshi ; Kawahara, Katsunobu</creator><creatorcontrib>Yamashita, Shin-ichi ; Tokuishi, Keita ; Hashimoto, Takafumi ; Moroga, Toshihiko ; Kamei, Mirei ; Ono, Kiyoshi ; Miyawaki, Michiyo ; Takeno, Shinsuke ; Chujo, Masao ; Yamamoto, Satoshi ; Kawahara, Katsunobu</creatorcontrib><description>We investigated the possibility of human epididymis 4(HE4) to predict survival for patients with pulmonary adenocarcinoma. One hundred and thirty-seven patients with pulmonary adenocarcinoma underwent surgery in our institute from 2000 to 2008. We used immunohistochemical analysis to determine the expression of HE4 and compared with the clinicopathological factors and survival. Serum levels of HE4 in lung adenocarcinoma were investigated by enzyme immunometric assay. Fifty-seven of 137 cases (41.6%) were HE4 positive. It was found that there was no correlation between HE4 expression by immunohistochemistry and clinicopathological factors, however, adenocarcinoma subtype was significantly associated with HE4 expression. Sera in lung adenocarcinoma were significantly higher than in healthy control. Five-year disease-free survival in the HE4-positive group (44.6%) was significantly different from that in the negative group (82.3%,
p
= 0.001) by immunohistochemistry. The five-year overall survival rate was 60.1% in the HE4-positive group, as compared with 90.8% in the HE4-negative group (
p
= 0.001). In multivariate Cox regression analysis, positive HE4 protein expression was a worse prognosis factor of disease-free and overall survival (HR = 3.7, 95%CI = [1.7–8.4],
p
= 0.001; HR = 5.5, 95%CI = [1.8–17.2],
p
= 0.003, respectively), in addition to nodal status as a powerful value. When HE4 expression in adenocarcinoma cases except the BAC were analyzed, nodal status and HE4 expression were independent prognostic factors in disease-free and overall survivals. These data showed that HE4 expression is associated with a worse prognosis and is a possible prognostic factor of lung adenocarcinoma.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-010-0118-5</identifier><identifier>PMID: 20953751</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adenocarcinoma - diagnosis ; Adenocarcinoma - metabolism ; Adenocarcinoma - mortality ; Aged ; beta-Defensins ; Biomarkers, Tumor - metabolism ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Case-Control Studies ; Epididymal Secretory Proteins - metabolism ; Female ; Gene expression ; Humans ; Lung cancer ; Lung Neoplasms - diagnosis ; Lung Neoplasms - metabolism ; Lung Neoplasms - mortality ; Male ; Medical prognosis ; Middle Aged ; Prognosis ; Proportional Hazards Models ; Proteins ; Regression Analysis ; Research Article ; Retrospective Studies ; Survival Rate</subject><ispartof>Tumor biology, 2011-04, Vol.32 (2), p.265-271</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2010</rights><rights>International Society of Oncology and BioMarkers (ISOBM) 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-690ccd6df8ddd17c97573828a911238b0f323b7a63ce1d4201372baa9a50023d3</citedby><cites>FETCH-LOGICAL-c436t-690ccd6df8ddd17c97573828a911238b0f323b7a63ce1d4201372baa9a50023d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/852723991?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>315,786,790,25783,27957,27958,37047,37048,44625</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20953751$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamashita, Shin-ichi</creatorcontrib><creatorcontrib>Tokuishi, Keita</creatorcontrib><creatorcontrib>Hashimoto, Takafumi</creatorcontrib><creatorcontrib>Moroga, Toshihiko</creatorcontrib><creatorcontrib>Kamei, Mirei</creatorcontrib><creatorcontrib>Ono, Kiyoshi</creatorcontrib><creatorcontrib>Miyawaki, Michiyo</creatorcontrib><creatorcontrib>Takeno, Shinsuke</creatorcontrib><creatorcontrib>Chujo, Masao</creatorcontrib><creatorcontrib>Yamamoto, Satoshi</creatorcontrib><creatorcontrib>Kawahara, Katsunobu</creatorcontrib><title>Prognostic significance of HE4 expression in pulmonary adenocarcinoma</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>We investigated the possibility of human epididymis 4(HE4) to predict survival for patients with pulmonary adenocarcinoma. One hundred and thirty-seven patients with pulmonary adenocarcinoma underwent surgery in our institute from 2000 to 2008. We used immunohistochemical analysis to determine the expression of HE4 and compared with the clinicopathological factors and survival. Serum levels of HE4 in lung adenocarcinoma were investigated by enzyme immunometric assay. Fifty-seven of 137 cases (41.6%) were HE4 positive. It was found that there was no correlation between HE4 expression by immunohistochemistry and clinicopathological factors, however, adenocarcinoma subtype was significantly associated with HE4 expression. Sera in lung adenocarcinoma were significantly higher than in healthy control. Five-year disease-free survival in the HE4-positive group (44.6%) was significantly different from that in the negative group (82.3%,
p
= 0.001) by immunohistochemistry. The five-year overall survival rate was 60.1% in the HE4-positive group, as compared with 90.8% in the HE4-negative group (
p
= 0.001). In multivariate Cox regression analysis, positive HE4 protein expression was a worse prognosis factor of disease-free and overall survival (HR = 3.7, 95%CI = [1.7–8.4],
p
= 0.001; HR = 5.5, 95%CI = [1.8–17.2],
p
= 0.003, respectively), in addition to nodal status as a powerful value. When HE4 expression in adenocarcinoma cases except the BAC were analyzed, nodal status and HE4 expression were independent prognostic factors in disease-free and overall survivals. These data showed that HE4 expression is associated with a worse prognosis and is a possible prognostic factor of lung adenocarcinoma.</description><subject>Adenocarcinoma - diagnosis</subject><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma - mortality</subject><subject>Aged</subject><subject>beta-Defensins</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Case-Control Studies</subject><subject>Epididymal Secretory Proteins - metabolism</subject><subject>Female</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - mortality</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Proteins</subject><subject>Regression Analysis</subject><subject>Research Article</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp1kE9LwzAYh4Mobk4_gBcpXjxV86dpmqOM6YSBHvQc0iQdGW1SkxX025vSqSB4CAm8T37v-z4AXCJ4iyBkdxERzFgOEUwHVTk9AnNUYJJDUsHj9B4rBa7IDJzFuIMQUc7LUzDDkFPCKJqD1UvwW-fj3qos2q2zjVXSKZP5Jluvisx89MHEaL3LrMv6oe28k-Ezk9o4r2RQ1vlOnoOTRrbRXBzuBXh7WL0u1_nm-fFpeb_JVUHKfV5yqJQudVNprRFTnFFGKlxJjhAmVQ0bgknNZEmUQbrAEBGGaym5pBBioskC3Ey5ffDvg4l70dmoTNtKZ_wQRUUJxiWmNJHXf8idH4JLwyUIM0w4RwlCE6SCjzGYRvTBdmk9gaAYDYvJsEgexWhYjMFXh-Ch7oz--fGtNAF4AmIqua0Jv53_T_0CmEGE1A</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Yamashita, Shin-ichi</creator><creator>Tokuishi, Keita</creator><creator>Hashimoto, Takafumi</creator><creator>Moroga, Toshihiko</creator><creator>Kamei, Mirei</creator><creator>Ono, Kiyoshi</creator><creator>Miyawaki, Michiyo</creator><creator>Takeno, Shinsuke</creator><creator>Chujo, Masao</creator><creator>Yamamoto, Satoshi</creator><creator>Kawahara, Katsunobu</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20110401</creationdate><title>Prognostic significance of HE4 expression in pulmonary adenocarcinoma</title><author>Yamashita, Shin-ichi ; Tokuishi, Keita ; Hashimoto, Takafumi ; Moroga, Toshihiko ; Kamei, Mirei ; Ono, Kiyoshi ; Miyawaki, Michiyo ; Takeno, Shinsuke ; Chujo, Masao ; Yamamoto, Satoshi ; Kawahara, Katsunobu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-690ccd6df8ddd17c97573828a911238b0f323b7a63ce1d4201372baa9a50023d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adenocarcinoma - diagnosis</topic><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma - mortality</topic><topic>Aged</topic><topic>beta-Defensins</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Case-Control Studies</topic><topic>Epididymal Secretory Proteins - metabolism</topic><topic>Female</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - mortality</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Proteins</topic><topic>Regression Analysis</topic><topic>Research Article</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamashita, Shin-ichi</creatorcontrib><creatorcontrib>Tokuishi, Keita</creatorcontrib><creatorcontrib>Hashimoto, Takafumi</creatorcontrib><creatorcontrib>Moroga, Toshihiko</creatorcontrib><creatorcontrib>Kamei, Mirei</creatorcontrib><creatorcontrib>Ono, Kiyoshi</creatorcontrib><creatorcontrib>Miyawaki, Michiyo</creatorcontrib><creatorcontrib>Takeno, Shinsuke</creatorcontrib><creatorcontrib>Chujo, Masao</creatorcontrib><creatorcontrib>Yamamoto, Satoshi</creatorcontrib><creatorcontrib>Kawahara, Katsunobu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamashita, Shin-ichi</au><au>Tokuishi, Keita</au><au>Hashimoto, Takafumi</au><au>Moroga, Toshihiko</au><au>Kamei, Mirei</au><au>Ono, Kiyoshi</au><au>Miyawaki, Michiyo</au><au>Takeno, Shinsuke</au><au>Chujo, Masao</au><au>Yamamoto, Satoshi</au><au>Kawahara, Katsunobu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of HE4 expression in pulmonary adenocarcinoma</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>32</volume><issue>2</issue><spage>265</spage><epage>271</epage><pages>265-271</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>We investigated the possibility of human epididymis 4(HE4) to predict survival for patients with pulmonary adenocarcinoma. One hundred and thirty-seven patients with pulmonary adenocarcinoma underwent surgery in our institute from 2000 to 2008. We used immunohistochemical analysis to determine the expression of HE4 and compared with the clinicopathological factors and survival. Serum levels of HE4 in lung adenocarcinoma were investigated by enzyme immunometric assay. Fifty-seven of 137 cases (41.6%) were HE4 positive. It was found that there was no correlation between HE4 expression by immunohistochemistry and clinicopathological factors, however, adenocarcinoma subtype was significantly associated with HE4 expression. Sera in lung adenocarcinoma were significantly higher than in healthy control. Five-year disease-free survival in the HE4-positive group (44.6%) was significantly different from that in the negative group (82.3%,
p
= 0.001) by immunohistochemistry. The five-year overall survival rate was 60.1% in the HE4-positive group, as compared with 90.8% in the HE4-negative group (
p
= 0.001). In multivariate Cox regression analysis, positive HE4 protein expression was a worse prognosis factor of disease-free and overall survival (HR = 3.7, 95%CI = [1.7–8.4],
p
= 0.001; HR = 5.5, 95%CI = [1.8–17.2],
p
= 0.003, respectively), in addition to nodal status as a powerful value. When HE4 expression in adenocarcinoma cases except the BAC were analyzed, nodal status and HE4 expression were independent prognostic factors in disease-free and overall survivals. These data showed that HE4 expression is associated with a worse prognosis and is a possible prognostic factor of lung adenocarcinoma.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>20953751</pmid><doi>10.1007/s13277-010-0118-5</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2011-04, Vol.32 (2), p.265-271 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_853226255 |
| source | Publicly Available Content Database |
| subjects | Adenocarcinoma - diagnosis Adenocarcinoma - metabolism Adenocarcinoma - mortality Aged beta-Defensins Biomarkers, Tumor - metabolism Biomedical and Life Sciences Biomedicine Cancer Research Case-Control Studies Epididymal Secretory Proteins - metabolism Female Gene expression Humans Lung cancer Lung Neoplasms - diagnosis Lung Neoplasms - metabolism Lung Neoplasms - mortality Male Medical prognosis Middle Aged Prognosis Proportional Hazards Models Proteins Regression Analysis Research Article Retrospective Studies Survival Rate |
| title | Prognostic significance of HE4 expression in pulmonary adenocarcinoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T20%3A32%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20HE4%20expression%20in%20pulmonary%20adenocarcinoma&rft.jtitle=Tumor%20biology&rft.au=Yamashita,%20Shin-ichi&rft.date=2011-04-01&rft.volume=32&rft.issue=2&rft.spage=265&rft.epage=271&rft.pages=265-271&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-010-0118-5&rft_dat=%3Cproquest_cross%3E2270899291%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c436t-690ccd6df8ddd17c97573828a911238b0f323b7a63ce1d4201372baa9a50023d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=852723991&rft_id=info:pmid/20953751&rfr_iscdi=true |